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Aim: Lower extremity deep venous thrombosis in the young adult is uncommon and has not 
been well studied in the literature. The aim of this study is to define risk factors for deep venous 
thrombosis among patients younger than 50 years of age, to compare them with a control group, 
and to suggest recommendations for the management and treatment of venous thrombosis in 
this particular group of patients.
Methods: From January 2003 to January 2011, 66 consecutive Lebanese patients (29 males 
and 37 females) younger than 50 years, diagnosed in an academic tertiary-care center with 
lower extremity deep venous thrombosis by color flow duplex scan, were retrospectively 
reviewed. Their age varied between 21 and 50 years (mean 38.7 years). The control group 
included 217 patients (86 males and 131 females) older than 50 years (range: 50–96 years; 
mean 72.9 years).
Results: The most commonly reported risk factors in the younger age group were inherited 
thrombophilia (46.9% compared with 13.8% in the control group; P , 0.001), pregnancy 
(18.2% compared with 0.5%; P , 0.001), treatment with estrogen drugs (13.6% compared 
with 2.3%; P = 0.001), and family history of venous thromboembolism (9.1% compared with 
3.8%; P = 0.084).
Conclusion: Inherited thrombophilia is the most commonly observed risk factor among 
patients younger than 50 years, with a prevalence of three times more than the control group. 
Young adults should be screened for thrombophilia even in the presence of transient acquired 
risk factors. Pregnancy and treatment with estrogen drugs essentially when associated with 
inherited thrombophilia represent a frequent cause of venous thrombosis among young female 
patients. Inferior vena cava abnormalities should be excluded in young patients with spontane-
ous proximal venous thrombosis especially when recurrent venous thrombosis or resistance to 
anticoagulation are observed.
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Introduction
Lower extremity deep venous thrombosis (DVT) is predominantly a disease of older 
age.1 The incidence of DVT increases exponentially with age for both idiopathic and 
secondary DVT rising nearly 90-fold between 15 and 80 years of age with a relative 
risk of 1.9 for each 10-year increase in age.2,3 It is uncommon in young adults and 
very rare before the age of 20 years.4 It is extremely rare in children occurring in only 
0.22% of hospitalized pediatric patients.5
The appropriate management of venous thrombosis requires a thorough knowledge 
of the underlying epidemiology and associated risk factors. Pathophysiology and risk 
factors for venous thrombosis among young adults vary considerably compared with 
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those reported for the general population. Very few papers 
assessing these risk factors in young adults have been pub-
lished in the literature.
The aim of this study is to define risk factors for DVT 
among Lebanese patients younger than 50 years, to compare 
them with a control group, and to propose recommendations 
for diagnosis, management, and treatment of venous throm-
bosis in this particular group of patients.
Materials and methods
From January 2003 to January 2010, 66 consecutive 
Lebanese patients (29 males and 37 females) younger than 
50 years of age, diagnosed in an academic tertiary-care 
center with lower extremity DVT using color flow duplex 
scan (Prosound Alpha 7 ALOKA, Zug, Switzerland), were 
retrospectively reviewed. Age varied from 21 to 50 years 
(mean 38.7 years). Fourteen patients (21.2%) were aged 
20–30 years of age, 22 patients (33.3%) were 30–40 years, 
and 38 patients (45.5%) were 40–50 years. Control group 
included 217 patients (86 males and 131 females) older 
than 50 years. The mean age of the patients in the control 
group was 72.9 years (range 50–96 years).
Thrombophilia was screened among patients with 
specific conditions highly suggestive of hypercoagulation 
states according to the guidelines proposed by the European 
Genetics Foundation, the Cardiovascular Educational and 
Research Trust, the International Union of Angiology and 
the Mediterranean League on Thromboembolism.6 These 
conditions were young age (#50 years), spontaneous, 
extended and recurrent DVT, family history of venous 
thromboembolism (VTE), oral contraceptives and estropro-
gestative treatment, long-haul air travel, pregnancy, inferior 
vena cava (IVC) congenital abnormalities, and resistance 
to anticoagulation.
A clinical research form was filled out with every patient, 
by a retrospective evaluation of clinical presentation and 
risk factors for venous thrombosis; data were entered and 
analyzed by SPSS Statistics (IBM Corporation, Somers, NY) 
software, version 13.0. A chi-square test was used to correlate 
between dichotomous variables, and a Fisher exact test was 
used in case of calculated values that were lower than five. 
Clinical presentation and risk factors for venous thrombosis 
were determined in the group of patients under the age of 50 
and in the control group.
Results
The great majority of patients younger than 50 years of 
age with confirmed venous thrombosis were   outpatients 
(72.7% compared with 56.2% in the control group; P = 0.0017). 
The side of lower extremity venous thrombosis did not statisti-
cally vary between the younger adult group and the control 
group. However, venous thrombosis was more commonly 
located at the ilio-femoral and femoro-popliteal level in 
the younger age group compared with the control group 
(62% comparing to 49.3%; P = 0.001) (Table 1). Three patients 
younger than 50 years (4.5%) and twelve patients older than 
50 years (5.5%) developed pulmonary embolism.
In these series, thrombophilia was the most commonly 
reported risk factor for venous thrombosis among patients 
younger than 50 years with a threefold increased rate com-
pared with the control group (46.7% compared with 13.8%; 
P , 0.001). Ninety four percent of the patients in the younger 
age group and all the patients in the control group tested for 
thrombophilia were positive. Prandoni demonstrated that the 
Table 1 Sociodemographic and deep venous thrombosis (DVT) characteristics of comparison groups
Characteristic Young patients 
N = 66
Older patients 
N = 217
P-value Total 
N = 283
Gender 
  Males 
  Females
 
29 (43.9%) 
37 (56.1%)
 
86 (39.6%) 
131 (60.4%)
0.533  
115 (40.6%) 
168 (59.4%)
Hospitalization 
  Yes 
  no
 
18 (27.3%) 
48 (72.7%)
 
95 (43.8%) 
122 (56.2%)
0.017  
113 (39.9%) 
170 (60.1%)
DVT side 
  Right side 
  Left side 
  Bilateral
 
21 (37.8%) 
39 (59.1%) 
6 (9.1%)
 
86 (39.6%) 
103 (47.5%) 
28 (12.9%)
0.248  
107 (37.8%) 
142 (50.2%) 
34 (12.0%)
DVT level 
  Calf 
  Femoro-popliteal 
  ilio-femoral
 
25 (37.9%) 
14 (21.1%) 
27 (40.9%)
 
110 (50.7%) 
67 (30.9%) 
40 (18.4%)
0.001  
135 (47.7%) 
81 (28.6%) 
67 (23.7%)
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frequency of thrombophilia outside the setting of surgery, 
trauma, or cancer is approximately 25%.7 This frequency 
was very high in the reported younger adult group (63.4%) 
and low in the control group (19.8%). Pregnancy and post-
partum were very important risk factors in the younger age 
group (18.2% compared with 0.5%; P , 0.001).
Treatment with estrogen drugs was more frequently 
reported among patients younger than 50 years of age 
compared with older patients (13.6% compared with 2.3%; 
P = 0.001). On the other hand, heart failure (P = 0.05) and 
immobilization (P = 0.02) were more commonly observed 
among older patients in the control group (Table 2).
In the reported study, patients younger than 50 years 
old exhibit higher genetic mutation rate for factors V R 
506 Q-Leiden (68.6% compared with 43.3%; P = 0.041) 
and for the homozygote and heterozygote forms of 
  methylenetetrahydrofolate reductase (MTHFR) C 677 T 
(11.4% compared with 3.3%; P = 0.063). The other pro-
thrombotic genetic mutations did not statistically vary in the 
two groups (Table 3).
Table 2 Risk factors for deep venous thrombosis in young age group and control group
Risk factors Young patients 
N = 66
Older patients 
N = 217
P-value Total 
N = 283
Thrombophilia 46.9% 13.8% ,0.001 61 (21.5%)
Thrombophilia testing* 33 (94.3%) 30 (100%) 0.495 63 (96.9%)
Pregnancy/postpartum 12 (18.2%) 1 (0.5%) ,0.001 13 (4.6%)
Obesity 10 (15.2%) 55 (25.3%) 0.085 65 (23.0%)
Family history of VTE 6 (9.1%) 7 (3.2%) 0.084 13 (4.6%)
Varicose veins 8 (12.1%) 24 (11.1%) 0.812 32 (11.3%)
Malignancy 6 (9.1%) 29 (13.4%) 0.356 35 (12.4%)
Personal history of VTE 10 (15.2%) 44 (20.3%) 0.353 54 (19.1%)
Long-haul air travel 3 (4.5%) 3 (1.4%) 0.142 6 (2.1%)
iVC congenital abnormalities 2 (0.9%) 1 (0.5%) 0.552 4 (1.4%)
Chronic obstructive pulmonary disease 0% 3 (1.4%) 1.000 3 (1.1%)
Alzheimer disease 0% 2 (0.9%) 1.000 2 (0.7%)
Chronic renal failure/dialysis 0% 6 (2.8%) 0.342 6 (2.1%)
Inflammatory bowel disease 2 (3.0%) 1 (0.5%) 0.137 3 (1.1%)
Hormonal/estrogen treatment 9 (13.6%) 5 (2.3%) 0.001 14 (4.9%)
Hip fracture 2 (3.0%) 15 (6.9%) 0.245 17 (6.0%)
Heart failure 0% 24 (11.1%) 0.005 24 (8.5%)
Post-operation/surgery 12 (18.2%) 39 (18.0%) 0.969 51 (18.0%)
immobilization 5 (7.6%) 43 (19.8%) 0.020 48 (17.0%)
Trauma 1 (1.5%) 6 (2.8%) 0.567 7 (2.5%)
Mean number of risk factors (SD) 1.83 (1.03%) 1.56 (1.01%) 0.058 1.63 (1.02)
$3 risk factors 13 (19.7%) 39 (18.0%) 0.751 52 (18.5%)
Notes: *Thrombophilia was tested in 35 young and 30 older individuals. Bold indicates results that are statistically significant or very suggestive.
Abbreviations: iVC, inferior vena cava; SD, standard deviation; VTE, venous thromboembolism.
Table 3 Prothrombotic genetic mutations in young age group and control group (when tested)
Thrombophilia Young patients 
N = 35
Older patients 
N = 30
P-value Total 
N = 65
Factor V R 506 Q-leiden any 24 (68.6%) 13 (43.3%) 0.041 37 (56.9%)
Homozygote 3 (8.6%) 2 (6.7%) 0.136 5 (7.7%)
Heterozygote 21 (60%) 11 (36.7%) 32 (49.2%)
MTHFR C 677 T any 14 (40%) 18 (60%) 0.108 32 (49.2%)
Homozygote 4 (11.4%) 1 (3.3%) 0.063 5 (7.7%)
Heterozygote 10 (28.6%) 17 (56.7%) 27 (41.5%)
MTHFR A 1298 C heterozygote 4 (11.4%) 6 (20.0%) 0.493 10 (15.4%)
  Prothrombin G 20210 A heterozygote 3 (8.6%) 1 (3.3%) 0.618 4 (6.2%)
  Factor V H 1299 R heterozygote 1 (2.9%) 1 (3.3%) 1.000 2 (3.1%)
Protein C deficiency 1 (2.9%) 0% 1.000 1 (1.5%)
Protein S deficiency 0% 1 (3.3%) 0.462 1 (1.5%)
increased homocysteine level 7 (20%) 9 (30%) 0.351 16 (24.6%)
Antiphospholipid syndrome 1 (2.9%) 0% 0.351 1 (1.5%)
Note: Bold indicates results that are statistically significant or very suggestive.
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Discussion
The development of clinically manifest venous thrombosis 
most often occurs with the convergence of multiple genetic 
and acquired risk factors. Young adults usually manifest 
severe forms of VTE. Determination of acquired and genetic 
risk factors for venous thrombosis among young adults is 
essential for appropriate management and treatment of this 
disease in this particular group of patients.
Thrombophilia, a hyper-coagulation state is common in 
the adult patient and occurs in approximately 50% to 70% of 
idiopathic VTE,8,9 in 39.5% to 53.5% of pregnant women,10,11 
and in 72% of individuals with travel-related VTE.12 The 
relative risks of developing a first episode of VTE in patients 
with documented acquired and genetic thrombophilia are 
increased from two- to elevenfold.13 In some series, inherited 
thrombophilia has been detected in 34% of young adults with 
venous thrombosis.14,15 In others, thrombophilia has been 
reported in 18.8% to 34% of young female patients with 
venous thrombosis and in 49% of young female patients 
with venous thrombosis and using oral contraceptives.16,17 
  Inherited thrombophilia has been recognized as a risk factor 
for pediatric VTE, but its significance has not been   thoroughly 
investigated.18
In a very recent study, thrombophilia has been observed 
in 7% of hospitalized children with VTE.5 In these series, 
inherited thrombophilia was the most common risk factor 
for lower extremity DVT in the younger age group occurring 
in 46.9% of the patients. The high rate of inherited throm-
bophilia observed in the younger age group is related to the 
high prevalence of factor V-Leiden, MTHFR C 677 T and A 
1298 C among Lebanese patients.19–21 Factor V-Leiden and 
MTHFR C 677 T mutation was more frequently detected 
among younger patients compared with older patients. The 
mutant allele was highly expressed among young adults with 
DVT and high-risk conditions for hypercoagulation state. The 
finding that patients with thrombophilia can harbor more 
than one prothrombotic genetic defect has further increased 
the relevance of the congenital thrombophilic states. Patients 
younger than 50 years of age should be screened for thrombo-
philia even in the presence of transient risk factor. We suggest 
testing for less frequently examined factor V H 1299 R and 
MTHFR A 1298 C in countries with very high prevalence 
of these mutations, and in young adults with extended VTE 
resistant to anti-coagulation, when not justified by the most 
common mutations. The incidence of venous thrombosis 
increases among pregnant women and among women using 
oral contraceptives and increases significantly when those 
women are carriers for prothrombotic genetic defects.
Prothrombin G 20210 A and factor V-Leiden mutation 
increases the risks of venous thrombosis 3.4- to 34-fold in 
pregnant women10,11,22–24 and 2.9- to 35-fold in women treated 
with oral contraceptives and estrogen.25,26 In the reported 
series, 31.8% of younger patients and 56.7% of younger 
female patients were pregnant or treated with oral contracep-
tives or estrogen drugs, emphasizing the role of hormonal 
impregnation in the pathogeneses of venous thrombosis. 
Ninety percent of these patients were carriers for genetic 
abnormalities, which further increased the risks of venous 
thrombosis. Because of this high risk for venous thrombosis, 
young females with a family history of VTE should be tested 
for prothrombotic genetic abnormalities prior to treatment 
initiation with oral contraceptives or estrogen. Nine percent 
of patients younger than 50 years observed in this study 
reported a family history of VTE. All younger patients with 
such a family history were tested for thrombophilia and were 
positive. This finding suggests screening for thrombophilia in 
all patients with a strong family history for VTE essentially 
when the thrombosis is spontaneous or when it occurs at a 
young age. When venous thrombosis develops spontane-
ously at a young age, it is commonly related to the presence 
of prothrombotic polymorphism, sometimes associated 
with congenital inferior vena cava abnormalities.27 Lambert 
et al identified these congenital anomalies in 5% of patients 
younger than 30 years presenting for unprovoked DVT.25 
The great majority of the patients were males and venous 
thrombosis occurred essentially after major physical activity.28 
IVC congenital malformations have been reported in 16.2% 
of young patients with iliac vein thrombosis.29 When these 
malformations are associated with inherited genetic defects 
leading to thrombophilia, the risks of venous thrombosis 
are increased several times.30–33 The three reported patients 
with IVC anomalies (two left-sided and one agenesis) in this 
study were young males, complaining of iliac venous throm-
bosis and were carriers for prothrombotic genetic mutations. 
Although uncommon, congenital inferior vena cava abnor-
malities should be excluded in young patients with spontane-
ous proximal DVT involving the iliac veins, essentially when 
resistance to anticoagulants, or recurrent venous thrombosis, 
are observed.34–40 When proximal venous thrombosis is located 
on the left side in young patients, May-Thurner syndrome 
should be suspected. Venous thrombosis risks increase when 
patients diagnosed with this syndrome are carriers for pro-
thrombotic genetic defects.41,42 Air travel is associated with 
a threefold higher risk for VTE with an 18% higher risk for 
each 2-hour increase in travel duration.43 In long-haul air 
flights, the quantitative risk of lower limbs venous thrombosis 
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is 1.6% per flight with low risk subjects and 5% per flight for 
high risk subjects.44 The three young adults observed in these 
series with venous thrombosis occurring after long-haul air 
travel were females, carriers for genetic polymorphism and 
using oral contraceptives. One of these young adults had a 
family history of VTE and underwent recent surgery. Beside 
thrombophilic disorders, the risks of venous thrombosis 
increase significantly in young adults when additive known 
risk factors such as obesity, recent surgery, history of VTE, 
and oral contraceptive treatment are reported.45
Maly et al demonstrated that the prevalence of occult 
cancer among patients under the age of 50 with VTE is low 
(1.8%).46 Inherited thrombophilia is more often found in the 
young adult, but risk of occult malignancy exists as well. 
Although uncommon in young adults, malignancy should be 
considered when venous thrombosis is idiopathic, resistant 
to anti-coagulation, when clinical and biological findings are 
suggestive of cancer and when thrombophilia testing does 
not indicate a significant prothrombotic risk for the devel-
opment of venous thrombosis. Following these rules, the 
authors observed a relatively high prevalence of malignancy 
among patients younger than 50 years of age with venous 
thrombosis (9.1%).
Inflammatory bowel disease is a generally accepted risk 
factor for VTE among the young patient.47 The mechanism 
underlying this association remains unclear. VTE may be 
observed during both active disease or periods of remission. 
It has been more frequently reported in patients with exten-
sive disease, colonic involvement, and with other associated 
extra-intestinal manifestations.48 Surgery and especially 
colorectal surgery carries an increased risk for venous throm-
bosis in patients with inflammatory bowel disease.49 Three 
young adults with venous thrombosis reported in this study 
have developed Crohn’s disease. One of them was 28 years 
old and the two others were 44 years old. A recent study 
demonstrated that the risks of VTE are increased twofold in 
patients with inflammatory bowel disease.50 Relative risks 
were particularly high among young patients and the risk 
incidence increases with age.50 In hospitalized children, 
inflammatory bowel disease has been reported to be one of 
the most common causes of VTE.51
Duration of the treatment of venous thrombosis in 
the young adult depends on the nature and extent of the 
thrombosis, the underlying risk factors, the presence of a 
previous VTE, the presence of congenital venous abnor-
malities, the presence and the severity of prothrombotic 
genetic mutation.52 Long-term treatment may be required 
to avoid recurrent venous thrombosis in young adults with 
idiopathic venous thrombosis, with continuous risk factors, 
with multiple episodes of venous thrombosis, and with severe 
inherited thrombophilia associated or not with congenital 
inferior vena cava and iliac abnormalities.
Conclusion
Inherited thrombophilia is the most commonly observed risk 
factor for venous thrombosis among patients younger than 
50 years, with an increased prevalence of at least threefold 
compared with the control group. It should be screened for in 
patients under the age of 50 even in the presence of a transient 
risk factor. Young adults usually present with severe forms 
of venous thrombosis. They should be assessed for acquired 
and also genetic factors, which would then suggest extending 
the duration of anticoagulant therapy in high risk patients, 
reducing the incidence of post-thrombotic syndrome and 
venous thromboembolic recurrence.
Pregnancy and treatment with oral contraceptives or 
estrogen drugs, especially when associated with inherited 
thrombophilia, represent a frequent cause of DVT among 
young female patients. Screening for thrombophilia among 
young females with strong family history of VTE before 
starting estrogen therapy is warranted. Congenital abnormali-
ties of the inferior vena cava and of the iliac veins should 
be excluded in young patients with spontaneous proximal 
DVT, involving the iliac veins, essentially when resistance 
to anticoagulant therapy or recurrent venous thrombosis 
is observed.
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